Drug intelligence / Profile preview

Suduvax

Development stage: Unknown
Lead developer: GC Biopharma
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

Suduvax is a live attenuated varicella (chickenpox) vaccine developed by Green Cross Corporation (now GC Biopharma). It contains the MAV/06 strain of the varicella-zoster virus, which was isolated from a Korean patient in 1989 and attenuated through multiple passages in human embryonic lung cells and guinea pig embryonic lung cells. Launched in 1994, it was South Korea's first and the world's second varicella vaccine. The vaccine is used to prevent chickenpox in healthy individuals and has been distributed globally, including through the Pan American Health Organization (PAHO). It is administered as a subcutaneous injection and has been used as a comparator in clinical trials for newer varicella vaccines like MG1111 (Barycela).

Brand names: Suduvax
Other names: varicella vaccine (live attenuated)

Beyond the preview

Go deeper on Suduvax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suduvax.

Explore the full profile